Regulated information
- 02 February 2012 - Paris (France)
Ipsen’s fourth quarter and full year 2011 sales and other significant developments
- 27 January 2012 - Paris (France)
Ipsen acknowledges Tanakan® delisting in France
- 24 January 2012 - Paris (France)
Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement
- 12 January 2012 - Paris (France)
Half-year statement of Ipsen's liquidity contract
- 05 January 2012 - Paris (France)
The total number of voting rights and total number of shares
- 05 January 2012 - Dijon and Paris (France)
Oncodesign and Ipsen enter into a research collaboration for the development of new therapeutic agents against the LRRK2 Parkinson's disease target
- 04 January 2012 - Paris (France)
Ipsen announces its corporate agenda for 2012
Ipsen’s fourth quarter and full year 2011 sales
Registration Document 2010
Publications
CONTACT US
Investor Relations
Tel.: +33 (0)1 58 33 51 29
Fax: +33 (0)1 58 33 50 63
Send an e-mail